ES2074323T3 - Nuevos derivados de piridilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion. - Google Patents

Nuevos derivados de piridilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.

Info

Publication number
ES2074323T3
ES2074323T3 ES92121126T ES92121126T ES2074323T3 ES 2074323 T3 ES2074323 T3 ES 2074323T3 ES 92121126 T ES92121126 T ES 92121126T ES 92121126 T ES92121126 T ES 92121126T ES 2074323 T3 ES2074323 T3 ES 2074323T3
Authority
ES
Spain
Prior art keywords
compounds
derivatives
thromboxane
group
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92121126T
Other languages
English (en)
Inventor
Rainer Dr Dipl-Chem Soyka
Thomas Dr Dipl-Chem Muller
Johannes Dr Dipl- Weisenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4141377A external-priority patent/DE4141377A1/de
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Application granted granted Critical
Publication of ES2074323T3 publication Critical patent/ES2074323T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Silicon Polymers (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

LA PRESENTE INVENCION CONCIERNE A NUEVOS DERIVADOS DE PIRIDILO, DE FORMULA, EN LA QUE, R6 ES UN GRUPO PIRIDINA, DADO EL CASO SUSTITUIDO POR UN GRUPO ALQUILO EN LA POSICION 3 O 4, Y X, Y, A, N Y R3 A R6, R7 Y R8, ESTAN DEFINIDOS COMO EN LA SOLICITUD 1, SUS ENANTIOMEROS, SUS ISOMEROS CIS Y TRANS, EN TANTO QUE, R4 Y R5 JUNTOS FORMAN UN ENLACE CARBONO-CARBONO, EL CUAL POSEE PROPIEDADES VALIOSAS. LOS COMPUESTOS DE LA FORMULA GENERAL I DE ARRIBA, EN LA QUE R7 REPRESENTA A UN GRUPO CIANO, E Y REPRESENTA A UN GRUPO ALCOXI, FENOXI, ALQUILTIO O FENILTIO, REPRESENTA A PRODUCTOS INTERMEDIOS, Y LOS COMPUESTOS RESTANTES QUE POSEEN PROPIEDADES FARMACOLOGICAS VALIOSAS, ESPECIALMENTE EL EFECTO ANTITROMBOTICO, ADEMAS, LOS NUEVOS COMPUESTOS REPRESENTAN AL MISMO TIEMPO ANTAGONISTAS DEL TROMBOXANO (TRA) E INHIBIDORES DE LA SINTESIS DEL TROMBOXANO (THS), E INHIBEN CON ELLO TAMBIEN LOS EFECTOS DERIVADOS DEL TROMBOXANO. ADEMAS POSEEN TAMBIEN UNA ACCION SOBRE LA PRODUCCION DE PGD2, PGE2 Y PGF2O, EN LOS TROMBOCITOSHUMANOS.
ES92121126T 1991-12-14 1992-12-11 Nuevos derivados de piridilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion. Expired - Lifetime ES2074323T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4141377A DE4141377A1 (de) 1991-12-14 1991-12-14 Neue pyridylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4216364A DE4216364A1 (de) 1991-12-14 1992-05-18 Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4216829A DE4216829A1 (de) 1991-12-14 1992-05-21 Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ES2074323T3 true ES2074323T3 (es) 1995-09-01

Family

ID=27203214

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92121126T Expired - Lifetime ES2074323T3 (es) 1991-12-14 1992-12-11 Nuevos derivados de piridilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.

Country Status (18)

Country Link
US (1) US5482948A (es)
EP (1) EP0547517B1 (es)
JP (1) JP2965425B2 (es)
KR (1) KR100227441B1 (es)
AT (1) ATE122658T1 (es)
AU (1) AU653455B2 (es)
CA (1) CA2085201C (es)
DE (3) DE4216364A1 (es)
DK (1) DK0547517T3 (es)
ES (1) ES2074323T3 (es)
FI (1) FI100882B (es)
HU (3) HUT68032A (es)
IL (1) IL104066A (es)
NO (1) NO179173C (es)
NZ (1) NZ245445A (es)
PL (3) PL171512B1 (es)
RU (1) RU2119915C1 (es)
TW (1) TW293816B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282252B6 (sk) * 1995-01-11 2001-12-03 Samjin Pharmaceutical Co., Ltd. Piperazínové deriváty a farmaceutický prostriedok s ich obsahom
DE69722360T2 (de) * 1996-06-29 2003-11-27 Samjin Pharm, Co. Piperazin-derivate und verfahren zu ihrer herstellung
KR20010012326A (ko) * 1997-05-07 2001-02-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 치환 3,3-디아미노-2-프로펜니트릴, 그것의 제조방법 및사용
US5955548A (en) * 1997-05-07 1999-09-21 Novo Nordisk A/S Substituted 3, 3-diamino-2-propenenitriles, their preparation and use
GB0022215D0 (en) * 2000-09-11 2000-10-25 Boehringer Ingelheim Pharma Method for the treatment of thromboembolic disorders in patients with aspirin« resistance
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
EP1450901A4 (en) * 2001-12-10 2005-05-25 Bristol Myers Squibb Co (1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US9388126B2 (en) 2012-07-19 2016-07-12 Drexel University Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3932403A1 (de) * 1989-05-12 1991-04-11 Thomae Gmbh Dr K Neue arylsulfonamide, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IL94805A (en) * 1989-06-28 1994-04-12 Ciba Geigy Ag Certain translocated carboxylic acids (a) Arylsulfonamide - and pyridyl - or imidazolil (), process for their preparation and pharmaceutical preparations containing them
DE4037112A1 (de) * 1990-11-22 1992-05-27 Thomae Gmbh Dr K Neue pyridylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
US5482948A (en) 1996-01-09
FI925665A0 (fi) 1992-12-14
DE4216829A1 (de) 1993-11-25
IL104066A (en) 1996-07-23
EP0547517A1 (de) 1993-06-23
FI100882B (fi) 1998-03-13
DK0547517T3 (da) 1995-09-04
PL171500B1 (en) 1997-05-30
HUT68032A (en) 1995-05-29
PL296896A1 (en) 1993-11-29
JPH06199793A (ja) 1994-07-19
AU653455B2 (en) 1994-09-29
NO179173C (no) 1996-08-21
ATE122658T1 (de) 1995-06-15
HU211230A9 (en) 1995-11-28
TW293816B (es) 1996-12-21
KR100227441B1 (ko) 1999-11-01
DE59202241D1 (de) 1995-06-22
HU9203949D0 (en) 1993-03-29
EP0547517B1 (de) 1995-05-17
CA2085201C (en) 2004-07-06
NO179173B (no) 1996-05-13
NO924800L (no) 1993-06-15
AU3005892A (en) 1993-06-17
PL171463B1 (pl) 1997-05-30
FI925665A (fi) 1993-06-15
NZ245445A (en) 1995-06-27
RU2119915C1 (ru) 1998-10-10
PL171512B1 (pl) 1997-05-30
NO924800D0 (no) 1992-12-11
DE4216364A1 (de) 1993-11-25
IL104066A0 (en) 1993-05-13
JP2965425B2 (ja) 1999-10-18
CA2085201A1 (en) 1993-06-15

Similar Documents

Publication Publication Date Title
ES2074323T3 (es) Nuevos derivados de piridilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
DE69501947D1 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
ATE78813T1 (de) Piperidinderivat, seine verwendung und diese enthaltende pharmazeutische zusammensetzung.
DE3782883D1 (de) Pyridincarboxamid-derivate und ihre verwendung als fungizides mittel.
ATE238273T1 (de) Alpha-aminoamidderivate die als analgetische mittel nützlich sind
WO2002034754A3 (en) Benzoxazinone derivatives, their preparation and use
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
DE69738907D1 (de) Neue diamidverbindungen und medikamente die diese enthalten
FI913067A0 (fi) Bisfosfonsyraderivat, deras framstaellning och anvaendning.
IL94347A0 (en) Arylsulphonamides,their preparation and pharmaceutical compositions containing them
TR24930A (tr) Kuslarin kontrol edilmesinde veya bununla ilgili gelismeler
DK0419676T3 (da) Thionaphthalenderivater, fremgangsmåde til fremstilling deraf og anti-allergipræparat indeholdende samme
ES2084756T3 (es) Nuevos derivados de piridilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
DK162982C (da) 1,4-dihydropyridinderivater og farmaceutiske praeparater indeholdende disse
ES531933A0 (es) Un procedimiento para preparar un derivado de imidazolinona
FR2674246B1 (fr) Nouveaux derives de l'acide alpha-methylene 5-thiazolacetique, leur procede de preparation et les intermediaires de ce procede, leur application a titre de fongicides et les compositions les renfermant.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 547517

Country of ref document: ES